Posted by Michael Wonder on 08 Aug 2022
Lurbinectedin receives the Innovative Medicine designation by the UK’s MHRA
5 August 2022 - PharmaMar has announced today that Zepzelca (lurbinectedin) has received the Innovation Passport (Innovative Medicine designation) by the Uk MHRA.
On 4 May 2022, PharmaMar announced it had submitted a conditional marketing authorisation application to the UK's MHRA for the treatment with lurbinectedin in adult patients with metastatic small cell lung cancer who have progressed following prior platinum-based chemotherapy based on data from the Phase 2 basket trial with lurbinectedin in monotherapy.
